The business model of Liquidia Corp revolves around the development and commercialization of novel products based on its versatile, proprietary PRINT® technology. The company utilizes its platform to design and manufacture precision-engineered particles and drug delivery systems for various therapeutic applications. Liquidia aims to address unmet medical needs by leveraging its expertise in materials science and engineering to enhance the efficacy and safety of pharmaceuticals. With a focus on partnerships and collaborations, Liquidia seeks to accelerate the development and commercialization of innovative therapeutics by leveraging the unique advantages of its PRINT® technology.

Liquidia Corp is primarily active in the pharmaceutical industry.

The main competitors of Liquidia Corp in the market are companies like Johnson & Johnson, Novartis, and Roche.

Liquidia Corp is a leading biopharmaceutical company specializing in the development of therapeutics using innovative particle engineering technology. Established in 2004, Liquidia has been focused on creating precision-engineered particles to enhance therapeutic outcomes. The company's proprietary PRINT® technology enables the design and production of precisely engineered particles with controllable size, shape, and composition. Liquidia develops a wide range of therapies for various diseases including respiratory conditions, such as pulmonary arterial hypertension (PAH). With a commitment to improving patient outcomes, Liquidia Corp continues to drive scientific innovation and advance the field of particle-based therapeutics.

Liquidia Corp has achieved several significant milestones since its inception. Notably, the company successfully completed its initial public offering (IPO) in July 2018, raising substantial funds to support its operations and future growth. Liquidia Corp also received FDA approval for its first product, LIQ861, in October 2019. This milestone marked a pivotal moment for the company, as LIQ861 is a potential breakthrough treatment for pulmonary arterial hypertension (PAH). Additionally, Liquidia Corp has established strategic partnerships and collaborations with renowned organizations, further enhancing its position in the biopharmaceutical industry. These achievements highlight the company's commitment to innovation and its potential for long-term success.

Liquidia Corp is primarily present in the United States.

Liquidia Corp represents values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing precision-engineered therapies, Liquidia's mission is to deliver transformative treatments to improve patients' lives. By leveraging their proprietary technology platform, PRINT®, Liquidia aims to address unmet medical needs and enhance therapeutic outcomes across various areas, including rare diseases and respiratory conditions. With a commitment to scientific excellence and a dedication to patient care, Liquidia Corp aims to set new standards in the field of biopharmaceuticals through cutting-edge research, strategic partnerships, and a patient-centered approach.

Analysts currently set an average price target of 46.58 USD for the Liquidia stock (median: 49.98 USD), implying -44.6 % versus the latest price. The consensus is based on 15 analyst ratings.

Liquidia Analyst Price Targets 2026

15 analysts currently rate the Liquidia stock: 13 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Liquidia to generate revenue of 725.12 M USD and earnings per share of 2.88 USD.

Liquidia Analyst Price Targets 2026

Converted at the current exchange rate, the Liquidia share trades at 75.40 EUR (86.80 USD).

The Liquidia share (LQDA) is listed on 3 stock exchanges, including: NASDAQ (LQDA), Frankfurt (LT4.F), München (LT4.MU).

Liquidia Corp is a pharmaceutical company based in Research Triangle Park, North Carolina, specializing in the development and commercialization of novel therapeutics using its proprietary particle technology platform. The company has two core areas of focus: pulmonary hypertension therapy and nanoparticle technology. In the field of pulmonary hypertension therapy, Liquidia is developing a novel therapy that focuses on the use of surfactant, a natural lung surface protein, to improve respiratory function in patients with this condition. In 2018, Liquidia was granted Orphan Drug Designation by the US Department of Health, which emphasizes the development of drugs for rare diseases. In the area of nanoparticle technology, Liquidia produces customized nanoparticulate materials to optimize drug delivery and therapy. Liquidia's patented technology enables more effective and targeted delivery of medications, thereby increasing the effectiveness of therapeutics. This technology also allows for shorter drug development timelines and reduced production costs, further strengthening Liquidia's business model. Liquidia has built a network of business partners to increase awareness of its technology within the industry. A growing list of partners utilize the Liquidia platform to develop drugs in their portfolio. Additionally, Liquidia itself is expanding its product portfolio by applying its technology to new therapy areas. Overall, Liquidia has established a strong position as an innovative pharmaceutical company by bringing a unique technology platform to market. Liquidia is also a member and active partner in the global healthcare community, discussing the discovery, development, and commercialization of therapeutics. Liquidia's business model is centered around creating high value by offering unique solutions to the needs of patients and the industry through its technology platform. The product range and business relationships of Liquidia provide a solid foundation for expanding and increasing value for patients. Therefore, Liquidia Corp's business model is strengthened by its patented technology platform, enabling increased sales, accelerated development of therapeutics, and ultimately helping patients with serious conditions. As an expanding company with focus areas in various therapy fields, there are significant opportunities and challenges, but Liquidia's strategy of focusing on innovation and collaboration points in the right direction for continued success in this dynamic market.

The expected revenue of Liquidia is 725.12 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Liquidia is 288.49 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Liquidia is currently 30.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Liquidia stock.

The price-to-sales ratio (P/S) of Liquidia is currently 11.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Liquidia stock.

The Eulerpool Quality Score for Liquidia is 3/10.

The ISIN of Liquidia is US53635D2027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Liquidia is A2JRNS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Liquidia is LQDA. The ticker symbol is used to trade Liquidia shares on the stock exchange.

Liquidia paid dividends every year for the past 0 years.

Liquidia is assigned to the 'Health' sector.

The dividends of Liquidia are distributed in USD.